• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

outlook

  1. Celgene plunges to new 52-week low

    What's the reason for Celgene going down even after beating the estimates and lifting 2018 outlook? Any thoughts? https://news.alphastreet.com/celgene-celg-stock-q3-2018-earnings/
    • anonymous
    • Thread
    • bristol-myers squibb celgene earnings mark alles merck novartis otezla outlook pharma revlimid
    • Replies: 59
    • Forum: Celgene

  2. Lilly sees pressure on pricing across all diabetes products

    Eli Lilly reports an increase in pharma sales and decline in Animal Health. Lifts 2018 earnings outlook. When answering an analyst question, Enrique Conterno said, "We continue to see pressure on pricing across all of our diabetes products".
    • anonymous
    • Thread
    • diabetes earnings eli lilly outlook pharma
    • Replies: 3
    • Forum: Eli Lilly

  3. Celgene's 4th quarter 2017 sales and profit beat estimates

    http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and Juno) multi-billion dollar acquisitions help the struggling Celgene in 2018 and beyond?
    • anonymous
    • Thread
    • cancer cancer treatment celgene earnings juno therapeutics otezla outlook revlimid tax reform
    • Replies: 3
    • Forum: Celgene

  4. Will Pfizer again attempt to acquire Allergan?

    When providing the outlook for 2018, Saunders said that Allergan faces LOE losses in 2018. But still it has got good long-term prospects. Saunders says that current stock price doesn't reflect Allergan's true value. Wall Street gives thumbs up to his speech.
    • anonymous
    • Thread
    • acquisition allergan guidance job cuts outlook pfizer teva
    • Replies: 4
    • Forum: Allergan

  5. A better outlook for 2018 from Lilly

    After raising the quarterly dividend recently, Lilly has provided outlook for 2018 and expects recently launched products to drive revenue. Dave Ricks says ""Looking to the future, the potential of our pipeline remains strong."
    • anonymous
    • Thread
    • dividend eli lilly guidance outlook pipeline
    • Replies: 4
    • Forum: Eli Lilly
Top Bottom
Back